Skip to main content
Premium Trial:

Request an Annual Quote

Evident Technologies Forms Quantum Dot Collaboration with NIST

NEW YORK, Aug. 24 (GenomeWeb News) - Evident Technologies said today that it has entered into a cooperative research and development agreement with the National Institute of Standards and Technology to investigate the use of quantum dot composite fluorescent standards for biotech instrumentation.

 

"A fluorescence standard is necessary, especially for clinical applications, where quantification is required," Clint Ballinger, CEO, of Evident, said in a statement. "It is nearly impossible to quantify the fluorescence from an assay today, but our collaboration with NIST should greatly advance the state of the art."

 

Under the CRADA, Evident will provide quantum dot composites to NIST for characterization.

 

Additional terms were not disclosed.

 

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.